JULY UPDATE: New indications for six drugs prescribers and pharmacists should know about

Cosentyxsecukinumab injection, Novartis.NEW INDICATION Treatment of moderate to severe hidradenitis suppurativa (acne inversa) in adults who have responded inadequately to conventional systemic hidradenitis suppurativa therapy. (Also approved earlier for use in thelso approved earlier for use in the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, active nonradiographic axial spondyloarthritis and juvenile idiopathic arthritis.)DOSAGE Moderate to severe hidradenitis suppurativa: 300 mg SC at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing (every 4 weeks). Based on clinical response, the maintenance dose can be increased to 300 mg every 2 weeks.Keytrudapembrolizumab solution for infusion, Merck.NEW INDICATION Treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults, in combination with gemcitabine-based chemotherapy. (Also approved earlier for numerous other indications; consult product monograph for details.)DOSAGE Biliary tract carcinoma: 200 mg every three weeks or 400 mg every six weeks, administered as an intravenous infusion over 30 minutes.Quliptaatogepant tablets, AbbVie.REVISED INDICATION Now indicated for the prevention of migraine in adults who have at least four migraine days per month. (Original stated indication was for the prevention of episodic migraine [< 15 migraine days per month] in adults.)DOSAGE Episodic migraine: Recommended dosage is 10 mg, 30 mg or 60 mg orally once daily (maximum 60 mg daily). Chronic migraine: Recommended dose is 60 mg orally once daily. Can be administered with or without food.Xeljanztofacitinib tablets, Pfizer.NEW INDICATIONS Treatment of active ankylosing spondylitis in adults who have responded inadequately to a biologic disease-modifying antirheumatic drug or when use of those therapies is inadvisable. Treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in children weighing ≥ 40 kg; intended for patients who have responded inadequately or are intolerant to tumour necrosis factor (TNF) inhibitors or when use of those therapies is inadvisable. (Also approved earlier for the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis in adults.)DOSAGE Ankylosing spondylitis: 5 mg twice daily. Polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis: 5 mg twice daily, as monotherapy or in combination with methotrexate.Xtandienzalutamide capsules, Astellas.NEW INDICATION Treatment of nonmetastatic castration-sensitive prostate cancer in patients with biochemical recurrence at high risk of metastasis. (Also approved earlier for prostate cancer in other situations; consult product monograph for details.)DOSAGE 160 mg (four 40 mg capsules) once daily, with or without food.Zoladex LAgoserelin implant (as goserelin acetate), TerSera Canada.NEW INDICATION Management of estrogen receptor (ER)-positive early breast cancer in pre- and perimenopausal women with a high risk of recurrence or advanced breast cancer. (Also indicated for use in the treatment of prostate cancer and for hormonal management of endometriosis.)DOSAGE ER-positive early breast cancer in pre- and perimenopausal women: One implant (10.8 mg goserelin) given by deep SC injection into the anterior abdominal wall every 12 weeks.

JULY UPDATE: New indications for six drugs prescribers and pharmacists should know about

Register for free access or login.

Related Topics